


Supplementary Table 1 Specific content of treatment plan

Project	Content
SOX	<ol style="list-style-type: none">1. Oxaliplatin: day 1, 130 mg/m², intravenous drip2. S-1: day 1 to day 14, orally, bid, body surface area (BSA) <1.25 m², 40 mg per dose; 1.25m² < BSA < 1.50 m², 50 mg per dose; BSA > 1.50 m², 60 mg per dose. 21 days for a cycle
XELOX	<ol style="list-style-type: none">1. Oxaliplatin: day 1, 130mg/m², intravenous drip2. Capecitabine: day 1 to day 14, orally, bid, 1000 mg/m² per dose, 21 days for a cycle
Sintilimab	200mg, intravenous drip, every three weeks
Toripalimab	3mg/kg, intravenous drip, every three weeks
Nivolumab	3mg/kg, intravenous drip, every three weeks
Tislelizumab	200mg, intravenous drip, every three weeks

Supplementary Table 2 Association between preoperative coagulation state and clinical parameters

	Non-hypercoagulation (n=54)	Hypercoagulation (n=50)	P value
Age (years) (mean ± SD)	54.93 ± 9.46	61.30 ± 7.88	< 0.001
Gender			0.358
Male	44	37	
Female	10	13	
BMI (kg/m ²) (mean ± SD)	22.96 ± 3.06	22.66 ± 2.53	0.579
Smoking status			0.126
Never smoker	36	40	
Ever smoker	18	10	
Drinking status			0.092
Never drinker	42	45	
Ever drinker	12	5	
Tumor location			0.460
Upper stomach	27	28	
Middle stomach	6	8	
Lower stomach	21	14	
Clinical T stage			0.771
cT3	31	29	
cT4	24	20	
Clinical N stage			0.753
cN1	35	31	
cN2	18	12	
cN3	5	3	
Pathological type			0.331
Non- signet ring cell carcinoma	40	41	
Signet ring cell carcinoma	14	9	
Immunotherapy regimen			0.067
Tislelizumab	37	40	
Sintilimab	8	5	
Nivolumab	6	0	
Toripalimab	3	5	



Supplementary Figure 1 The cut-off value of age.